Browse By: Country ι Category ι Latest Reports ι Tag
Home  »  GlobalData

GlobalData Market Research Reports

GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

Combining precision with innovation, our research and consulting solutions ensure our clients stay at the forefront of their markets by integrating accurate market forecasts and analysis on the latest trends and developments with the unrivalled expertise of our analyst teams. Among other benefits, our informed industry perspectives help clients understand how to generate the maximum return from their key markets, identify opportunities from emerging trends, and devise strategies for growth with confidence. 



Mozambique Upstream Fiscal and Regulatory Report
Mozambique Upstream Fiscal and Regulatory ReportSummaryMozambique Upstream Fiscal and Regulatory Report, GlobalDatas latest release, presents the essential information relating to the terms which govern investment into Mozambiques upstream oil and gas sector. The report sets out in detail the contractual framework which firms must operate in the industry, clearly defining factors affecting profitability and quantifying the states take from hydrocarbon production. Considering political, economic and industry specific variables, the report also analyses future trends for Mozambiques upstream oil and gas investment climate.Scope- Overview of current fiscal terms governing upstream oil and gas operations in Mozambique- Information on the legal framework and governing bodies administering the i
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Laredo Petroleum, Company Intelligence Report
Laredo Petroleum, Company Intelligence ReportSummaryLaredo Petroleum, Inc. (Laredo) is an independent energy company in the US. It focuses on the exploration, development and acquisition of oil and liquids-rich natural gas in the US Permian Basin. The Permian Basin is one of the most prolific oil and liquids-rich natural gas regions of the US. The company is currently drilling locations in the Upper Wolfcamp, Middle Wolfcamp, Lower Wolfcamp and Cline Shales. Besides the Permian Basin, Laredo also undertakes operations in other areas within its core operating regions.Scope- Key Highlights: This section provides detailed analysis on the companys overall oil and gas value chain, new projects, growth opportunities, new ventures, assets performance, Capex funding, geographical results of oil an
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
LINN Energy LLC, Company Intelligence Report
LINN Energy LLC, Company Intelligence ReportSummaryLINN Energy LLC (LINN Energy) is an independent oil and natural gas company. It develops and acquires oil, Natural Gas Liquids (NGL) and gas assets. Its operations are spread across the US, with prominent assets in Wyoming, Utah, Colorado, East Texas and California. In August 2014, the company had a proved and probable reserve base of 7,900 billion cubic feet equivalent (bcfe). It is headquartered in Houston, Texas. Its core development and exploration activities are categorized into seven operating regions: the Rockies, the Mid-Continent, Hugoton Basin, California, Permian Basin, Michigan and Illinois-Antrim Shale, and East Texas.Scope- Key Highlights: This section provides detailed analysis on the companys overall oil and gas value chain
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Mexico Zaap Project Panorama - Oil and Gas Upstream Analysis Report
Mexico Zaap Project Panorama - Oil and Gas Upstream Analysis ReportSummaryMexico Zaap Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of the f
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Mexico Maloob Project Panorama - Oil and Gas Upstream Analysis Report
Mexico Maloob Project Panorama - Oil and Gas Upstream Analysis ReportSummaryMexico Maloob Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of t
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Mexico Ku Project Panorama - Oil and Gas Upstream Analysis Report
Mexico Ku Project Panorama - Oil and Gas Upstream Analysis ReportSummaryMexico Ku Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of the field
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Refining Industry Outlook in Middle East and Africa to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries
Refining Industry Outlook in Middle East and Africa to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned RefineriesSummary"Refining Industry Outlook in Middle East and Africa to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on crude oil refining industry in Middle East and Africa. The report provides refinery details such as refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and planned refineries in the region. The report also provides refinery capital expenditure outlook for Middle East and Africa till 2019. The report provides key country comparisons
Published Date: Feb 2015
Published By: GlobalData

Price: $5000
Refining Industry Outlook in South America, Central America and Caribbean to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries
Refining Industry Outlook in South America, Central America and Caribbean to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned RefineriesSummary"Refining Industry Outlook in South America, Central America and Caribbean to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on crude oil refining industry in South America, Central America and Caribbean. The report provides refinery details such as refinery name, country and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and planned refineries in the region. The report also provides refinery capital expenditure outlook for South Americ
Published Date: Feb 2015
Published By: GlobalData

Price: $5000
Global Planned Refining Industry Outlook to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Planned Refineries
Global Planned Refining Industry Outlook to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Planned RefineriesSummary"Global Planned Refining Industry Outlook to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Planned Refineries" is a comprehensive report on global planned crude oil refining industry. The report provides refinery details such as refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all planned refineries. The report also provides refinery capital expenditure outlook at global as well as regional level by year and by key countries till 2019. The report also provides comparison of key countries based on contribution to global as wel
Published Date: Feb 2015
Published By: GlobalData

Price: $5000
End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015
End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" provides data on the End-Stage Kidney Disease (end-stage renal disease or ESRD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Nephropathy Global Clinical Trials Review, H1, 2015
Nephropathy Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analys
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polycystic Kidney Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polycystic Kidney Disease. This report is built using data and information sourced from pro
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Proteinuria Global Clinical Trials Review, H1, 2015
Proteinuria Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Proteinuria Global Clinical Trials Review, H1, 2015" provides data on the Proteinuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Proteinuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Proteinuria. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analys
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Renal Failure Global Clinical Trials Review, H1, 2015
Renal Failure Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Renal Failure Global Clinical Trials Review, H1, 2015" provides data on the Renal Failure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Renal Failure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Failure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-ho
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Renal Stones/Calculi Global Clinical Trials Review, H1, 2015
Renal Stones/Calculi Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Renal Stones/Calculi Global Clinical Trials Review, H1, 2015" provides data on the Renal Stones/Calculi clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Renal Stones/Calculi. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Stones/Calculi. This report is built using data and information sourced from proprietary databases, prima
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2014
Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2014SummaryGlobalDatas Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2014 report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity (PE), venture financing and partnership transactions recorded in the power industry in Q4 2014. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments and geographies. The report also provides information on the top PE, venture capital (VC) and advisory firms in the power industry.GlobalData derived the data presented in this r
Published Date: Feb 2015
Published By: GlobalData

Price: $1500
Power Monthly Deal Analysis - January 2015: M&A and Investment Trends
Power Monthly Deal Analysis - January 2015: M&A and Investment TrendsSummaryGlobalData's Power Monthly Deal Analysis - January 2015: M&A and Investment Trends report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the power industry in January 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the power industry.Data presented in this report is derived from GlobalData
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Saudi Arabia Power Market Outlook to 2030, Update 2015 - Market Trends, Regulations, and Competitive Landscape
Saudi Arabia Power Market Outlook to 2030, Update 2015 - Market Trends, Regulations, and Competitive LandscapeSummaryThis report elaborates Saudi Arabias power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the Saudi Arabian power markets regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Saudi Arabia on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Financial performance of the leading power companies is also analyzed in the report.Sc
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014SummaryGlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the
Published Date: Feb 2015
Published By: GlobalData

Price: $1500
Mauritania Tevet Project Panorama - Oil and Gas Upstream Analysis Report
Mauritania Tevet Project Panorama - Oil and Gas Upstream Analysis ReportSummaryMauritania Tevet Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcom
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Athletes Foot (Tinea Pedis) Global Clinical Trials Review, H1, 2015
Athletes Foot (Tinea Pedis) Global Clinical Trials Review, H1, 2015SummaryGlobalDatas clinical trial report, Athletes Foot (Tinea Pedis) Global Clinical Trials Review, H1, 2015" provides data on the Athletes Foot (Tinea Pedis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Athletes Foot (Tinea Pedis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Athletes Foot (Tinea Pedis). This report is built using data and information sourced
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
Siemens Healthcare - Product Pipeline Analysis, 2015 Update
Siemens Healthcare (formerly Siemens Medical Solutions) is a global medical device company. It undertakes the design, development, manufacture and distribution of medical devices and technologies for diagnostic markets. It offers imaging equipment, healthcare information systems, management consulting, and support services. It has a comprehensive portfolio of medical solutions, ranging from medical imaging, in vitro diagnostics, and interventional systems to clinical IT. It conducts operations in North America, Africa, Europe, Asia and Australia. Siemens Healthcare is a business unit of Siemens AG and is headquartered in Erlangen, Germany.The company focuses on innovation to develop new products and expand its markets in BRIC countries (Brazil, Russia, India and China). With an intent to
Published Date: Feb 2015
Published By: GlobalData

Price: $750
Instrumentation Laboratory Company - Product Pipeline Analysis, 2015 Update
Instrumentation Laboratory Company (IL) is a medical device company with focus on in vitro diagnostics (IVD) devices. The company carries out the development, manufacture and distribution of IVD instruments, related reagents and controls for use in hospitals and clinical laboratories. Its major products include critical care systems, hemostasis systems and information management systems. It also offers various quality control productsand services such as data management, clinical support and product support. The company has operations in the UK, France, Italy, Uruguay, Belgium, Germany, Mexico, Japan, Austria, the Netherlands, Hong Kong, and the US, among other countries.  IL is a subsidiary of Werfen Group and is headquartered in Bedford, Massachusetts, the US. This report is a
Published Date: Feb 2015
Published By: GlobalData

Price: $750
Beckman Coulter, Inc. - Product Pipeline Analysis, 2015 Update
Beckman Coulter, Inc. (Beckman) is a medical device company. It undertakes the manufacture and marketing of biomedical laboratory instruments, software and supplies that simplify, automate and innovate complex biomedical tests. Its products are used in a wide range of applications such as medical research, clinical trials and drug discovery, and diagnostic laboratories in hospitals. The company has three divisions, namely, Research and Discovery, Diagnostics and Industrial. It operates across the US, Canada, Europe and Asia. Its products are sold in over 160 countries worldwide. The company has an installed base of over 275,000 clinical and research systems operating in laboratories around the world. Beckman is a subsidiary of Danaher Corporation, and is headquartered in California, the
Published Date: Feb 2015
Published By: GlobalData

Price: $750
Oncgnostics GmbH - Product Pipeline Analysis, 2015 Update
Oncgnostics GmbH (Oncgnostics) is an in-vitro diagnostic company. It is involved in developing molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. The company’s technology GynTect is a new system based on   the detection of epigenetic biomarkers, especially the methylation of specific DNA regions. Its GynTect is a new triage assay which allows a fast and reliable detection of cervical precancerous lesions and cancer. The company also focuses on various other types of cancers such as ovarian cancer and head and neck tumors.  It has its operations all over the country. Oncgnostics is headquartered in Jena, Germany. This report is a source for data, analysis, and actionable intelligence on the company&rs
Published Date: Feb 2015
Published By: GlobalData

Price: $750
Hemiplegia Global Clinical Trials Review, H1, 2015
Hemiplegia Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Hemiplegia Global Clinical Trials Review, H1, 2015" provides data on the Hemiplegia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemiplegia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemiplegia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by
Published Date: Feb 2015
Published By: GlobalData

Price: $2500
W. L. Gore and Associates, Inc. - Product Pipeline Analysis, 2015 Update
W. L. Gore & Associates, Inc. (Gore) carries out the manufacture and marketing of fluoro-polymer products for the medical, electronics, nuclear, fabrics and industrial markets. The company’s medical division provides surgeons and patients a variety of surgical products and medical OEM products. Its implants portfolio includes materials and components that solve complex medical problems in vascular, endovascular, interventional, general surgery and cardiothoracic, oral and orthopedic procedures. Gore caters to aerospace, automotive, chemical processing, computer, telecommunications, electronics, energy, environmental, industrial, manufacturing, military, pharmaceutical, biotechnology, and textile markets. The company has manufacturing facilities in the US, Scotland, Germany, Chi
Published Date: Feb 2015
Published By: GlobalData

Price: $750
EKF Diagnostics Holdings plc (EKF) - Product Pipeline Analysis, 2015 Update
EKF Diagnostics Holdings plc (EKF Diagnostics) is a medical device company. It designs, develops, manufactures, and commercializes chemical reagents, and analyzers for the measurement of glucose, lactate, hematocrit, hemoglobin, and glycated hemoglobin. The company’s product portfolio comprises HbA1c analyzers, hemoglobin analyzers, glucose analyzers, lactate analyzers, rapid and sepsis testing kits, reagents, and biomarkers. These products find application in blood banks, general surgeries, pharmacies, hospitals, diabetes clinics, laboratories, and sports medicine.  It offers these products in more than 100 countries throughout the world through subsidiaries, and distributors under brands such as Quo-Lab, HemataStat, DiaSpect, STAT-Site, UltraCrit, Lactate Scout+, QuPID, True
Published Date: Feb 2015
Published By: GlobalData

Price: $750
FUJIFILM Medical Systems USA, Inc. - Product Pipeline Analysis, 2015 Update
FUJIFILM Medical Systems USA, Inc. (Fujifilm Medical) is a medical device company. It is one of the leading providers of medical imaging and information products and technologies for the diagnostic imaging markets. Its products acquire, process, manage, and store diagnostic images and related data. The company’s major products include radiology systems, cardiovascular systems, direct radiography (DR) systems, computed radiology (CR) systems (digital X-ray), endoscopes, digital mammography systems, ultrasound systems and dry imagers and film/screen. The company also provides integration and technical support services. Fujifilm Medical is a wholly owned subsidiary of FUJIFILM Holdings America Corporation and is headquartered in Stamford, Connecticut, the US. This report is a sourc
Published Date: Feb 2015
Published By: GlobalData

Price: $750
Genentech, Inc. - Product Pipeline Analysis, 2015 Update
Genentech, Inc. (Genentech) is one of the world's leading biotech companies. The company undertakes research, development, manufacture, and marketing of biotherapeutics. Genentech focuses on developing drugs for unmet medical needs in the areas of cancer, immunological diseases and angiogenic disorders. Some of its major products include Rituxan, Avastin, Herceptin, Tarceva, Lucentis, Xolair, Pulmozyme and Activase. Its research activities focus on areas of cancer, metabolism, immunology, infectious disease and neuroscience. Its clinical development pipeline includes small molecules, monoclonal antibodies, and antibody drug conjugates. The company operates as a wholly owned subsidiary of Roche following its acquisition in 2009. The company is headquartered in South San Francisco, Califor
Published Date: Feb 2015
Published By: GlobalData

Price: $750
Nigeria Oso Project Panorama - Oil and Gas Upstream Analysis Report
Nigeria Oso Project Panorama - Oil and Gas Upstream Analysis ReportSummaryNigeria Oso Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of the f
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Nigeria Ovo Project Panorama - Oil and Gas Upstream Analysis Report
Nigeria Ovo Project Panorama - Oil and Gas Upstream Analysis ReportSummaryNigeria Ovo Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of the f
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Salamander Energy plc, Company Intelligence Report
Salamander Energy plc, Company Intelligence ReportSummarySalamander Energy (Salamander) is an upstream oil and gas company with a specific focus on exploration and production in Asia. The company was formed in 2005 and has its core assets in Thailand and Indonesia, with additional interests in Malaysia and Laos. In Thailand, Salamander has acreage positions in Greater Bualuang, which consists of the Bualuang oil field, reportedly the companys flagship producing asset. In Indonesia, the company has interests in licenses located in the Greater Kerendan area and North Kutei. Apart from these core assets, Salamander also has interests in the Kutai Production Sharing Contract (PSC) and the south Sokang PSC, in east Kalimantan and Natuna Sea respectively. In Thailand, the companys non-core asset
Published Date: Feb 2015
Published By: GlobalData

Price: $1000
Refining Industry Outlook in Asia and Oceania to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries
Refining Industry Outlook in Asia and Oceania to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned RefineriesSummary"Refining Industry Outlook in Asia and Oceania to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on crude oil refining industry in Asia and Oceania. The report provides refinery details such as refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and planned refineries in the region. The report also provides refinery capital expenditure outlook for Asia and Oceania till 2019. The report provides key country comparisons within a region based o
Published Date: Feb 2015
Published By: GlobalData

Price: $5000
Refining Industry Outlook in Europe to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries
Refining Industry Outlook in Europe to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned RefineriesSummary"Refining Industry Outlook in Europe to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on crude oil refining industry in Europe. The report provides refinery details such as refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and planned refineries in the region. The report also provides refinery capital expenditure outlook for Europe till 2019. The report provides key country comparisons within a region based on contribution to regional refining capa
Published Date: Feb 2015
Published By: GlobalData

Price: $5000
Refining Industry Outlook in North America to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries
Refining Industry Outlook in North America to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned RefineriesSummary"Refining Industry Outlook in North America to 2019 - Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on crude oil refining industry in North America. The report provides refinery details such as refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and planned refineries in the region. The report also provides refinery capital expenditure outlook for North America till 2019. The report provides key country comparisons within a region based on contributi
Published Date: Feb 2015
Published By: GlobalData

Price: $5000
EpiCast Report: Insomnia - Epidemiology Forecast to 2023
EpiCast Report: Insomnia - Epidemiology Forecast to 2023SummaryGlobalData epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156 total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. GlobalData epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated 23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%. GlobalData epidemiologists forecast that
Published Date: Feb 2015
Published By: GlobalData

Price: $3995
Clean Coal Technologies, Update 2014 - Global Market Size, Trends, Regulations and Key Country Analysis to 2025
GlobalData, the industry analysis specialist, has released its latest research, “Clean Coal Technologies, Update 2014 Global Market Size, Trends, Regulations and Key Country Analysis to 2025”, which provides in-depth analysis of the clean coal technologies market at global and key country level. The term “clean coal” usually refers to the minimization of carbon emissions and other pollutants in coal-fired power generation. Supercritical (SC), Ultra Supercritical (USC), Circulating Fluidized Bed (CFB) technologies, Integrated Gasification Combined Cycle (IGCC) are termed as clean coal technologies. These can be used to improve the efficiency of existing coal-fired power plants and reduce the amount of CO2 emissions for the same amount of power generated. Scop
Published Date: Feb 2015
Published By: GlobalData

Price: $3995
Spinocerebellar Ataxias Global Clinical Trials Review, H1, 2015
Spinocerebellar Ataxias Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Spinocerebellar Ataxias Global Clinical Trials Review, H1, 2015" provides data on the Spinocerebellar Ataxias clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinocerebellar Ataxias. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinocerebellar Ataxias. This report is built using data and information sourced from proprietary d
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Tay-Sachs Disease Global Clinical Trials Review, H1, 2015
Tay-Sachs Disease Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Tay-Sachs Disease Global Clinical Trials Review, H1, 2015" provides data on the Tay-Sachs Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tay-Sachs Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tay-Sachs Disease. This report is built using data and information sourced from proprietary databases, primary and secondar
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
W&T Offshore, Inc., Company Intelligence Report
W&T Offshore, Inc., Company Intelligence ReportSummaryW&T Offshore is Houston-based oil and natural gas company that is actively involved in the exploration, development and acquisition of oil and natural gas properties, located onshore and offshore in the US. W&T Offshore is primarily operating in the Deepwater Gulf Of Mexico (GOM), the GOM shelf, and the Permian Basin of West Texas. As of December 31, 2013, the companys 1P reserves totaled 119.6 million barrels of oil equivalent (mmboe) and its estimated 2P reserves totaled 169.6 mmboe. W&T Offshore reported overall production of 18 mmboe in 2013, representing an annual increase of around 5% over the 17.1 mmboe of production recorded in 2012.W&T Offshore possess 268,000 net acres in Deepwater GOM as of November 11, 2014. As of December 3
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015" provides data on the Non Alcoholic Fatty Liver Disease (NAFLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non Alcoholic Fatty Liver D
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Nonerosive Reflux Disease (NERD) Global Clinical Trials Review, H1, 2015
Nonerosive Reflux Disease (NERD) Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Nonerosive Reflux Disease (NERD) Global Clinical Trials Review, H1, 2015" provides data on the Nonerosive Reflux Disease (NERD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nonerosive Reflux Disease (NERD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nonerosive Reflux Disease (NERD). This report is built using da
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015
Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015" provides data on the Post Operative Nausea And Vomiting clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Post Operative Nausea And Vomiting. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Post Operative Nausea And Vomiting. This report is buil
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Steatohepatitis Global Clinical Trials Review, H1, 2015
Steatohepatitis Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Steatohepatitis Global Clinical Trials Review, H1, 2015" provides data on the Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Steatohepatitis. This report is built using data and information sourced from proprietary databases, primary and secondary research
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Alpha - Antitrypsin Deficiency Global Clinical Trials Review, H1, 2015
Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H1, 2015SummaryGlobalDatas clinical trial report, Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H1, 2015" provides data on the Alpha- Antitrypsin Deficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Alpha- Antitrypsin Deficiency. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Alpha- Antitrypsin Deficiency. This report is built using data and informati
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Power Monthly Deal Analysis - December 2014: M&A and Investment Trends
Power Monthly Deal Analysis - December 2014: M&A and Investment TrendsSummaryGlobalData's Power Monthly Deal Analysis - December 2014: M&A and Investment Trends report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the power industry in December 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the power industry.Data presented in this report is derived from GlobalD
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Partnerships, Licensing, Investments and M&A Deals and Trends for December 2014 in Pharmaceuticals
Partnerships, Licensing, Investments and M&A Deals and Trends for December 2014 in PharmaceuticalsSummaryGlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for December 2014 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provid
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Becker Muscular Dystrophy Global Clinical Trials Review, H1, 2015
Becker Muscular Dystrophy Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Becker Muscular Dystrophy Global Clinical Trials Review, H1, 2015" provides data on the Becker Muscular Dystrophy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Becker Muscular Dystrophy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Becker Muscular Dystrophy. This report is built using data and information sourced from pro
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Cystinosis Global Clinical Trials Review, H1, 2015
Cystinosis Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Cystinosis Global Clinical Trials Review, H1, 2015" provides data on the Cystinosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cystinosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cystinosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Glomerulonephritis Global Clinical Trials Review, H1, 2015
Glomerulonephritis Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis. This report is built using data and information sourced from proprietary databases, primary and sec
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H1, 2015
Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H1, 2015" provides data on the Glycogen Storage Disorders (GSD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glycogen Storage Disorders (GSD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glycogen Storage Disorders (GSD). This report is built using da
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Microalbuminuria Global Clinical Trials Review, H1, 2015
Microalbuminuria Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Microalbuminuria Global Clinical Trials Review, H1, 2015" provides data on the Microalbuminuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Microalbuminuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Microalbuminuria. This report is built using data and information sourced from proprietary databases, primary and secondary res
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Pilonidal Sinus Global Clinical Trials Review, H1, 2015
Pilonidal Sinus Global Clinical Trials Review, H1, 2015SummaryGlobalData's clinical trial report, Pilonidal Sinus Global Clinical Trials Review, H1, 2015" provides data on the Pilonidal Sinus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pilonidal Sinus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pilonidal Sinus. This report is built using data and information sourced from proprietary databases, primary and secondary research
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Pakistan Qadirpur Project Panorama - Oil and Gas Upstream Analysis Report
Pakistan Qadirpur Project Panorama - Oil and Gas Upstream Analysis ReportSummaryPakistan Qadirpur Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outc
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Nigeria Okwok Project Panorama - Oil and Gas Upstream Analysis Report
Nigeria Okwok Project Panorama - Oil and Gas Upstream Analysis ReportSummaryNigeria Okwok Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of t
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Iraq Rumaila Project Panorama - Oil and Gas Upstream Analysis Report
Iraq Rumaila Project Panorama - Oil and Gas Upstream Analysis ReportSummaryIraq Rumaila Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome of the
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Vietnam Chim Sao (Blackbird) and Dua Project Panorama - Oil and Gas Upstream Analysis Report
Vietnam Chim Sao (Blackbird) and Dua Project Panorama - Oil and Gas Upstream Analysis ReportSummaryVietnam Chim Sao (Blackbird) and Dua Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Iraq Barda Rash Project Panorama - Oil and Gas Upstream Analysis Report
Iraq Barda Rash Project Panorama - Oil and Gas Upstream Analysis ReportSummaryIraq Barda Rash Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the economic outcome
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Russia Upstream Fiscal and Regulatory Report
“Russia Upstream Fiscal and Regulatory Report”, GlobalData’s latest release, presents the essential information relating to the terms which govern investment into Russia’s upstream oil and gas sector. The report sets out in detail the licensing framework under which firms must operate in the industry, clearly defining factors affecting profitability and quantifying the state’s take from hydrocarbon production. Considering political, economic and industry specific variables, the report also analyses future trends for Russia’s upstream oil and gas investment climate. Scope Overview of the fiscal and regulatory regime governing upstream oil and gas operations in Russia Detail on legal framework and governing bodies administering the industry
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015"" provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). This report is built using dat
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Optic Neuropathy Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Optic Neuropathy Global Clinical Trials Review, H1, 2015"" provides data on the Optic Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Optic Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Optic Neuropathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of i
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015"" provides data on the Keratoconjunctivitis sicca (Dry Eye) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Keratoconjunctivitis sicca (Dry Eye). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Keratoconjunctivitis sicca (Dry Eye). This report is built using data and information sourced from proprietary databases
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Macular Edema Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Macular Edema Global Clinical Trials Review, H1, 2015"" provides data on the Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Macular Edema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Macular Edema. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry expe
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Neovascular Glaucoma Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Neovascular Glaucoma Global Clinical Trials Review, H1, 2015"" provides data on the Neovascular Glaucoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neovascular Glaucoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neovascular Glaucoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Optic Neuritis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Optic Neuritis Global Clinical Trials Review, H1, 2015"" provides data on the Optic Neuritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Optic Neuritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Optic Neuritis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Alcoholic Hepatitis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H1, 2015"" provides data on the Alcoholic Hepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Alcoholic Hepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Alcoholic Hepatitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Choledocholithiasis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Choledocholithiasis Global Clinical Trials Review, H1, 2015"" provides data on the Choledocholithiasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Choledocholithiasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Choledocholithiasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Cholelithiasis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Cholelithiasis Global Clinical Trials Review, H1, 2015"" provides data on the Cholelithiasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholelithiasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cholelithiasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Cirrhosis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Cirrhosis Global Clinical Trials Review, H1, 2015"" provides data on the Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cirrhosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Crohns Disease Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Crohn's Disease Global Clinical Trials Review, H1, 2015"" provides data on the Crohn’s Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Crohn’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Crohn’s Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDa
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Dyspepsia Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Dyspepsia Global Clinical Trials Review, H1, 2015"" provides data on the Dyspepsia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dyspepsia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyspepsia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Fecal Incontinence Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Fecal Incontinence Global Clinical Trials Review, H1, 2015"" provides data on the Fecal Incontinence clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fecal Incontinence. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fecal Incontinence. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's t
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Gastroparesis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Gastroparesis Global Clinical Trials Review, H1, 2015"" provides data on the Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroparesis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry expe
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Hepatic Encephalopathy Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Hepatic Encephalopathy Global Clinical Trials Review, H1, 2015"" provides data on the Hepatic Encephalopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic Encephalopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic Encephalopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis b
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015"" provides data on the Irritable Bowel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable Bowel Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house an
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Congo Republic Ikalou Project Panorama - Oil and Gas Upstream Analysis Report
Congo Republic Ikalou Project Panorama - Oil and Gas Upstream Analysis ReportSummaryCongo Republic Ikalou Project Panorama, GlobalDatas latest release, presents a comprehensive overview of the asset. This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.Scope- Overview of the asset based on an analysis of the economic indicators- Key financial indicators including Net Present Value and Internal Rate of Return- Review of factors affecting the econo
Published Date: Jan 2015
Published By: GlobalData

Price: $1000
Global Wind Turbine Value Chain - Production, Market Share, Competitive Landscape and Market Size to 2020
Global Wind Turbine Value Chain Production, Market Share, Competitive Landscape and Market Size to 2020” is the latest report from industry analysis specialists GlobalData, offering a comprehensive understanding of the wind power industry. The report provides an overview of the global wind power market, examining major drivers and restraints and global wind power capacity and generation data broken down by region, country, and segment (onshore/offshore). It also looks at the wind turbine market, covering global average turbine size, price, market size, and manufacturer share in terms of installations. The report discusses the global wind turbine value chain, examining the key components of a wind turbine: the rotor blade, gearbox, tower, and generator. It analyzes the product
Published Date: Jan 2015
Published By: GlobalData

Price: $3995
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France
GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in France. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts. France&rsq
Published Date: Jan 2015
Published By: GlobalData

Price: $1995
Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, “Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015"" provides data on the Axial Spondyloarthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Axial Spondyloarthritis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analys
Published Date: Jan 2015
Published By: GlobalData

Price: $2500
Colombia Power Market Outlook to 2030, Update 2014 - Market Trends, Regulations and Competitive Landscape
This report elaborates Colombia’s power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the Colombian power market’s regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Colombia on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Financial performance of the leading power companies is also analyzed in the report. Scope Snapshot of the country’s power sector across parameters macro economics, supply security, g
Published Date: Jan 2015
Published By: GlobalData

Price: $1500
Ukraine Power Market Outlook to 2030, Update 2014 - Market Trends, Regulations, and Competitive Landscape
Ukraine Power Market Outlook to 2030, Update 2014 - Market Trends, Regulations, and Competitive Landscape Summary This report elaborates Ukraines power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of Ukraines power markets regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Ukraines on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Scope Snapshot of the countrys power sector across parameters - macro economics,
Published Date: Jan 2015
Published By: GlobalData

Price: $1500
Switzerland Power Market Outlook to 2030, Update 2014 - Market Trends, Regulations and Competitive Landscape
This report elaborates Switzerlands power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of Switzerlands power markets regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Switzerlands on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Scope Snapshot of the countrys power sector across parameters macro economics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario
Published Date: Jan 2015
Published By: GlobalData

Price: $1500
Sweden Power Market Outlook to 2030, Update 2014 - Market Trends, Regulations, and Competitive Landscape
This report elaborates Swedens power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the Swedish power markets regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Sweden on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Financial performance of the leading power companies is also analyzed in the report. Scope Snapshot of the countrys power sector across parameters macro economics, supply security, generation infrastructure,
Published Date: Jan 2015
Published By: GlobalData

Price: $1500
PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and Market Analysis to 2023
PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023
PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti
Published Date: Dec 2014
Published By: GlobalData

Price: $6995
PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023
PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the an
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023
PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With th
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023
PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the an
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023
PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the an
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023
PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023SummaryIrritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients quality of life (QOL). In terms of volume, the IBS market is a large, albeit na
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023
PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023SummaryIrritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients quality of life (QOL). In terms of volume, the IBS market is a large, albeit na
Published Date: Dec 2014
Published By: GlobalData

Price: $6995
PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023
PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023SummaryIrritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients quality of life (QOL). In terms of volume, the IBS market is a large, albeit na
Published Date: Dec 2014
Published By: GlobalData

Price: $4995
Iguratimod-T-614 (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Iguratimod/T-614 (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-T
Published Date: Dec 2014
Published By: GlobalData

Price: $3495
Carrizo Oil & Gas, Inc., Company Intelligence Report
Carrizo Oil & Gas, Inc., Company Intelligence ReportSummaryCarrizo Oil & Gas (Carrizo) is a Huston-based company that is actively involved in the exploration, development and acquisition of oil and natural gas properties located in the US. On February 22, 2013, Carrizo closed its operation in the UK and sold all its assets to Iona Energy for an agreed price of US$184 million.Carrizo is currently focusing primarily on the Eagle Ford Shale in South Texas, the Niobrara Formation in Colorado, the Marcellus Shale in Pennsylvania, and the Utica Shale in Ohio.Scope- Key Highlights: This section provides detailed analysis on the companys overall oil and gas value chain, new projects, growth opportunities, new ventures, assets performance, Capex funding, geographical results of oil and gas operatio
Published Date: Dec 2014
Published By: GlobalData

Price: $1000
Enbrel (etanercept) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Enbrel (etanercept) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti
Published Date: Dec 2014
Published By: GlobalData

Price: $3495
Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti
Published Date: Dec 2014
Published By: GlobalData

Price: $3495
Remicade (infliximab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Remicade (infliximab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the an
Published Date: Dec 2014
Published By: GlobalData

Price: $3495
Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti
Published Date: Dec 2014
Published By: GlobalData

Price: $3495
Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With
Published Date: Dec 2014
Published By: GlobalData

Price: $3495